Journal article
Abstract CT157: Phase 1 dose-escalation study of linclatamig, a LY6G6D×CD3 T cell-engaging bispecific antibody, in patients with colorectal cancer
Marwan Fakih, Jayesh Desai, Iosune Baraibar, Ignacio Melero, David Spigel, Eric Chen, Ben Markman, Arshdeep Pooni, Amy A Lo, Rosanna S Kwok, Stephanie Hilz, Zao Li, Pranay Dogra, Neha N Shah, Andrew G Polson, Douglas Leipold, Wei Zou, Mengsong Li, Luciana Molinero, Simon Heidegger Show all
Cancer Research | American Association for Cancer Research (AACR) | Published : 2025
Abstract
Abstract Background: Lymphocyte antigen 6 complex locus G6D (LY6G6D) is a promising target in metastatic colorectal cancer (mCRC) due to its differentiated expression in tumor vs. normal tissues, and higher prevalence in microsatellite-stable CRC. Linclatamig (or BLYG8824A) is a humanized, IgG1, LY6G6D × CD3 T cell-engaging bispecific antibody (TCB), that binds to LY6G6D and CD3+ T cells, forming an immunologic synapse to facilitate T cell-mediated killing of LY6G6D+ cells. This study evaluated the safety, pharmacokinetics (PK), biomarkers, and anti-tumor activity of linclatamig in patients (pts) with LY6G6D+ mCRC. ..
View full abstract